98 related articles for article (PubMed ID: 21520487)
1. Genotoxicity of dietary, environmental and therapeutic topoisomerase II poisons is uniformly correlated to prolongation of enzyme DNA residence.
Kalfalah FM; Mielke C; Christensen MO; Baechler S; Marko D; Boege F
Mol Nutr Food Res; 2011 May; 55 Suppl 1():S127-42. PubMed ID: 21520487
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells.
Snyder RD; Gillies PJ
Environ Mol Mutagen; 2002; 40(4):266-76. PubMed ID: 12489117
[TBL] [Abstract][Full Text] [Related]
3. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
4. Cells lacking DNA topoisomerase II beta are resistant to genistein.
López-Lazaro M; Willmore E; Austin CA
J Nat Prod; 2007 May; 70(5):763-7. PubMed ID: 17411092
[TBL] [Abstract][Full Text] [Related]
5. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
Wang SJ; Peyrollier K; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):281-8. PubMed ID: 17372087
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.
Bandele OJ; Osheroff N
Biochemistry; 2008 Nov; 47(45):11900-8. PubMed ID: 18922022
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.
Markovits J; Linassier C; Fossé P; Couprie J; Pierre J; Jacquemin-Sablon A; Saucier JM; Le Pecq JB; Larsen AK
Cancer Res; 1989 Sep; 49(18):5111-7. PubMed ID: 2548712
[TBL] [Abstract][Full Text] [Related]
8. Bioflavonoids as poisons of human topoisomerase II alpha and II beta.
Bandele OJ; Osheroff N
Biochemistry; 2007 May; 46(20):6097-108. PubMed ID: 17458941
[TBL] [Abstract][Full Text] [Related]
9. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
Ganapathi R; Constantinou A; Kamath N; Dubyak G; Grabowski D; Krivacic K
Mol Pharmacol; 1996 Aug; 50(2):243-8. PubMed ID: 8700130
[TBL] [Abstract][Full Text] [Related]
10. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
[TBL] [Abstract][Full Text] [Related]
11. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro.
Constantinou A; Stoner GD; Mehta R; Rao K; Runyan C; Moon R
Nutr Cancer; 1995; 23(2):121-30. PubMed ID: 7644381
[TBL] [Abstract][Full Text] [Related]
12. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
13. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
[TBL] [Abstract][Full Text] [Related]
14. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
[TBL] [Abstract][Full Text] [Related]
15. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
16. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
17. Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
Binaschi M; Farinosi R; Austin CA; Fisher LM; Zunino F; Capranico G
Cancer Res; 1998 May; 58(9):1886-92. PubMed ID: 9581829
[TBL] [Abstract][Full Text] [Related]
18. Acrylamide catalytically inhibits topoisomerase II in V79 cells.
Sciandrello G; Mauro M; Caradonna F; Catanzaro I; Saverini M; Barbata G
Toxicol In Vitro; 2010 Apr; 24(3):830-4. PubMed ID: 20006698
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides.
Duca M; Guianvarc'h D; Oussedik K; Halby L; Garbesi A; Dauzonne D; Monneret C; Osheroff N; Giovannangeli C; Arimondo PB
Nucleic Acids Res; 2006; 34(6):1900-11. PubMed ID: 16598074
[TBL] [Abstract][Full Text] [Related]
20. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons.
Borgnetto ME; Tinelli S; Carminati L; Capranico G
J Mol Biol; 1999 Jan; 285(2):545-54. PubMed ID: 9878428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
